Figure 5.

CD37 decrease does not hamper CAR T cells’ cytotoxicity.

Equal amounts of (a) WT and rituximab-resistant (RR) or (b) NTC and sg1 cells were stained with CellTrace™ Violet and incubated for 16 h with various effector to target (E:T) ratios of CD37 CAR-T cells. Cell viability was assessed with flow cytometry following PI staining. Data represent mean ± SD of % cytotoxicity of CD37 CAR-T cells after subtracting cytotoxicity of unmodified T-cells. Statistical analysis was performed using 2-way ANOVA with Tukey’s post hoc test. Experiments were repeated at least four times (c) Kaplan–Meier survival curve of mice inoculated on day 0 with 5 × 10⁵ Raji WT (left panel, n = 3 mice per group) or RR (right panel, n = 4 mice per group) after two doses of 10 × 10⁶ CAR-T cells injected intravenously on day 1 and 4. Statistical significance was determined using the long-rank test.